Table of Contents
<< Previous Issue | Jul 2011 (Vol: 2011, Issue: 7) | Next Issue >> |
- Section: Cartoons
-
Hardball
- Section: Licensing
-
Gilead and Tibotec Partner to Develop and Commercialise HIV Combination Drugs
-
BMS Licenses Innate Pharma’s Phase I Immuno-Oncology Monoclonal Antibody
- Section: Mergers & Acquisitions
-
Allozyne to Go Public via Reverse Merger with Poniard Pharmaceuticals
-
Valeant to Buy Sanofi’s Dermik Skincare Unit for US$425 M
-
Valeant Continues its Acquisition Spree with Agreement to Buy Janssen’s Ortho Dermatologics Division
-
Allergan Agrees to Acquire Vicept Therapeutics in US$275 M Deal
-
Roche Broadens its Cancer Diagnostics Portfolio with mtm laboratories Acquisition
- Section: Research & Development
-
Genentech Gain Rights to Acquire Forma Therapeutics’ Preclinical Cancer Programme in Innovative Deal
-
AstraZeneca and PTC Therapeutics Sign Cancer Drug Discovery Pact
-
Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi
-
Micromet Signs US$1 B BiTE® Antibody Collaboration with Amgen
- Section: Royalties
-
Astellas Divests Prosidion’s DPP-IV Inhibitor Patent Assets to Royalty Pharma